Asset Details
Do you wish to reserve the book?
Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome
Do you wish to request the book?
Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome
2024
Overview
The results of this phase 3 trial of the effect of olezarsen, a drug that targets
APOC3
mRNA, on plasma triglyceride levels and acute pancreatitis in familial chylomicronemia syndrome support further clinical research.
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Aged
/ Apolipoprotein C-III - blood
/ Female
/ Genetics
/ Humans
/ Hyperlipoproteinemia Type I - blood
/ Hyperlipoproteinemia Type I - complications
/ Hyperlipoproteinemia Type I - drug therapy
/ Hypertriglyceridemia - blood
/ Hypertriglyceridemia - drug therapy
/ Lipids
/ Male
/ Oligonucleotides - adverse effects
/ Oligonucleotides - therapeutic use
/ Patients
/ Placebos
/ Plasma
